The University of Chicago Header Logo

Connection

Michael H. Davidson to Coronary Artery Disease

Back to Details
This is a "connection" page, showing publications Michael H. Davidson has written about Coronary Artery Disease.
Michael H. Davidson
Connection Strength
5.785
Coronary Artery Disease
  1. The Battle of the HDL Subfractions. Cardiovasc Revasc Med. 2019 11; 20(11):943-944.
    View in: PubMed
    Score: 0.514
  2. The Role of Genetics in Cardiovascular Risk Reduction: Findings From a Single Lipid Clinic and Review of the Literature. Cardiovasc Revasc Med. 2020 02; 21(2):200-204.
    View in: PubMed
    Score: 0.497
  3. Cardiovascular risk factors in a patient with diabetes mellitus and coronary artery disease: therapeutic approaches to improve outcomes: perspectives of a preventive cardiologist. Am J Cardiol. 2012 Nov 06; 110(9 Suppl):43B-49B.
    View in: PubMed
    Score: 0.316
  4. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial. Cardiovasc Drugs Ther. 2012 Aug; 26(4):349-58.
    View in: PubMed
    Score: 0.311
  5. The role of cardiologists in the management of patients with diabetes is evolving owing to the close relationship between diabetes and CAD. Introduction. Am J Cardiol. 2011 Aug 02; 108(3 Suppl):1B-2B.
    View in: PubMed
    Score: 0.290
  6. Apolipoprotein A-I therapy promise, challenges, and disappointment. J Am Coll Cardiol. 2011 Mar 01; 57(9):1120-1.
    View in: PubMed
    Score: 0.279
  7. Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study. Arterioscler Thromb Vasc Biol. 2010 Sep; 30(9):1873-6.
    View in: PubMed
    Score: 0.269
  8. Focus on HDL as a therapeutic target for CAD risk reduction. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):1E-2E.
    View in: PubMed
    Score: 0.258
  9. Novel targets that affect high-density lipoprotein metabolism: the next frontier. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):52E-7E.
    View in: PubMed
    Score: 0.258
  10. Atherosclerosis surrogate imaging trials come of age: for better or for worse? Curr Cardiol Rep. 2008 Nov; 10(6):521-5.
    View in: PubMed
    Score: 0.240
  11. Introduction. U.S. incidence of coronary artery disease. Am J Cardiol. 2008 Jun 16; 101(12A):1F-2F.
    View in: PubMed
    Score: 0.233
  12. Niacin therapy: an evolving paradigm for the management of mixed dyslipidemia and low high-density lipoprotein cholesterol. Introduction. Am J Cardiol. 2008 Apr 17; 101(8A):1B-2B.
    View in: PubMed
    Score: 0.231
  13. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther. 2008 Mar; 6(3):391-409.
    View in: PubMed
    Score: 0.229
  14. High-density lipoprotein metabolism: potential therapeutic targets. Am J Cardiol. 2007 Dec 03; 100(11 A):n32-40.
    View in: PubMed
    Score: 0.225
  15. How low to target LDL? Nat Clin Pract Endocrinol Metab. 2006 Aug; 2(8):414-5.
    View in: PubMed
    Score: 0.205
  16. Comparative effects of lipid-lowering therapies. Prog Cardiovasc Dis. 2004 Sep-Oct; 47(2):73-104.
    View in: PubMed
    Score: 0.180
  17. Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome. Am J Cardiol. 2004 Jun 03; 93(11A):3C-11C.
    View in: PubMed
    Score: 0.176
  18. Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. J Clin Lipidol. 2021 Sep-Oct; 15(5):629-648.
    View in: PubMed
    Score: 0.146
  19. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation. 1998 Aug 18; 98(7):628-33.
    View in: PubMed
    Score: 0.118
  20. Prognostic value of normal regadenoson stress perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2013 Dec 21; 15:108.
    View in: PubMed
    Score: 0.086
  21. The efficacy of colesevelam HCl in the treatment of heterozygous familial hypercholesterolemia in pediatric and adult patients. Clin Ther. 2013 Aug; 35(8):1247-52.
    View in: PubMed
    Score: 0.083
  22. Statistical genetic analysis of serological measures of common, chronic infections in Alaska Native participants in the GOCADAN study. Genet Epidemiol. 2013 Nov; 37(7):751-7.
    View in: PubMed
    Score: 0.083
  23. Novel developments in omega-3 fatty acid-based strategies. Curr Opin Lipidol. 2011 Dec; 22(6):437-44.
    View in: PubMed
    Score: 0.074
  24. Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region. Am J Cardiol. 2011 Mar 15; 107(6):906-11.
    View in: PubMed
    Score: 0.070
  25. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008 Apr 29; 51(17):1632-41.
    View in: PubMed
    Score: 0.058
  26. Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy. Am J Cardiol. 2008 Apr 17; 101(8A):27B-35B.
    View in: PubMed
    Score: 0.058
  27. Relationship of traditional and nontraditional cardiovascular risk factors to coronary artery calcium in type 2 diabetes. Diabetes. 2007 Mar; 56(3):849-55.
    View in: PubMed
    Score: 0.053
  28. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med. 2006 Mar 23; 354(12):1253-63.
    View in: PubMed
    Score: 0.050
  29. Statin safety: an assessment using an administrative claims database. Am J Cardiol. 2006 Apr 17; 97(8A):61C-68C.
    View in: PubMed
    Score: 0.049
  30. Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol. 2005 Aug 15; 96(4):556-63.
    View in: PubMed
    Score: 0.048
  31. Prospective analysis of mannose-binding lectin genotypes and coronary artery disease in American Indians: the Strong Heart Study. Circulation. 2004 Feb 03; 109(4):471-5.
    View in: PubMed
    Score: 0.043
  32. Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events. Curr Atheroscler Rep. 2003 Sep; 5(5):418-22.
    View in: PubMed
    Score: 0.042
  33. Collaborative multidisciplinary workshop report: the role of epidemiology studies in determining a possible relationship between Chlamydia pneumoniae infection and atherothrombotic diseases. J Infect Dis. 2000 Jun; 181 Suppl 3:S430-1.
    View in: PubMed
    Score: 0.008
  34. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol. 1996 Aug 15; 78(4):409-14.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.